Welcome to our dedicated page for Ascendis Pharma A/S SEC filings (Ticker: ASND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ascendis Pharma A/S's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ascendis Pharma A/S's regulatory disclosures and financial reporting.
Ascendis Pharma A/S reported 5-year (Week 266) results from its Phase 2 PaTH Forward Trial of TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism. The company states long-term treatment showed sustained efficacy and safety while replicating key systemic actions of natural parathyroid hormone.
The 59-patient trial, mostly post-surgical cases, followed a 4-week randomized, double-blind, placebo-controlled period with a 262-week open-label extension. Ascendis reports that TransCon PTH maintained normalized and stable urine calcium, serum calcium, quality of life, and bone mineral density, enabling independence from conventional active vitamin D and calcium therapy.
Additional measures included renal function by estimated glomerular filtration rate, bone mineral density by DXA, symptom burden via the Hypoparathyroidism Patient Experience Scale, and broader health-related quality of life using the SF-36 survey, alongside safety monitoring of treatment-emergent adverse events and 24-hour urine calcium.
Ascendis Pharma A/S reported granting new equity incentives to employees through a warrant program. On June 9, 2026, the board approved a total of 27,030 warrants under Appendix 1a of the company’s Articles of Association, and amended the Articles to allow this grant.
Each warrant allows the holder to subscribe for one ordinary share at an exercise price of US $213.23 per share, matching the closing share price on the grant date. Vesting is time-based: 25% vests on the one-year anniversary of the grant and the remaining 75% vests in equal monthly installments over the following 36 months, subject to continued service and certain earlier-vesting exit events.
After this grant, warrants to subscribe for an additional 1,553,563 shares remain available for future grants under the company’s Articles of Association.
Ascendis Pharma A/S EVP & Chief Financial Officer Scott Thomas Smith made an open-market purchase of 100 Ordinary Shares on June 2, 2026 at $219.00 per share.
Following this transaction, he directly holds 4,367 Ordinary Shares of Ascendis Pharma A/S.
Ascendis Pharma A/S director Jean Jacques Bienaime reported three open-market purchases of Ordinary Shares. On May 29, 2026, he bought a total of 500 shares at prices ranging from $222.30 to $223.76 per share. Following these transactions, he directly holds 900 Ordinary Shares of Ascendis Pharma, with no sales reported in this filing.
Ascendis Pharma A/S Executive Vice President and Chief Financial Officer Scott Thomas Smith executed an open-market purchase of 250 Ordinary Shares on May 29, 2026 at $223.32 per share. Following this transaction, his directly held position increased to 4,267 Ordinary Shares.
Ascendis Pharma A/S executive Scott Thomas Smith, EVP & Chief Financial Officer, has reported his equity holdings in an amended Form 3. He directly holds 4,017 Ordinary Shares.
He also holds Restricted Stock Units covering 9,552, 3,197 and 4,246 underlying Ordinary Shares, which begin vesting on March 1, 2027, with some vesting in two or three equal annual installments. In addition, he holds fully vested, currently exercisable warrants over 14,504, 22,755, 27,000, 45,000 and 45,000 Ordinary Shares at exercise prices ranging from $37.18 to $176.28 per share with expiration dates between 2027 and 2031. The filing lists holdings only and does not show any new purchases or sales.
Ascendis Pharma A/S director Jean Jacques Bienaimé reported open-market purchases of the company’s Ordinary Shares. On May 26, 2026, he bought a total of 400 shares in two transactions, at weighted average prices of $236.235 and $239.3675 per share, executed across multiple trades within narrow intraday price ranges.
Janus Henderson Group plc reports beneficial ownership of 3,719,452 American Depositary Shares of Ascendis Pharma A/S. The filing states these shares represent 6.0% of the class and that Janus Henderson's affiliated asset managers hold shared voting and dispositive power over 3,719,452 ADSs. The filing disclaims rights to dividends or sale proceeds associated with the Managed Portfolios.
Ascendis Pharma ownership update: Capital International Investors reports beneficial ownership of 2,013,285 shares, representing 3.2% of common stock. The filing states 61,977,408 shares believed outstanding and shows sole voting power of 2,005,343 and sole dispositive power of 2,013,285.
Ascendis Pharma A/S granted new equity incentives to employees. On May 12, 2026, the board approved 31,250 warrants for certain employees under Appendix 1a of the Articles of Association. Each warrant allows purchase of one ordinary share at an exercise price of US $237.65, the closing share price on the grant date.
Twenty‑five percent of the warrants vest one year after grant, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service and potential earlier vesting upon certain exit events. After this grant, warrants to subscribe for an additional 1,580,593 shares remain available for future grants under the Articles of Association.